Tiziana Life Sciences【TLSA】銘柄情報

Tiziana Life Sciences Ltd (TLSA) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

1.16

( - )

買値

1.15

売値

1.25

出来高

0.00 日の範囲 0.00

1.08 52 週間の範囲 2.60

時価総額

149.997M

前日終値

1.16

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 195,761

発行済株式数

129,307,401

配当利回り

PER

-7.96

1 株当たり利益 (EPS)

-0.16

歳入

純利益

-18.43M

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clin... Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer’s disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.tizianalifesciences.com

本社

London, United Kingdom

設立

Tiziana Life Sciences Ltd is listed in the Healthcare sector of the ナスダック市場 with ticker TLSA. The last closing price for Tiziana Life Sciences was US$1.16. Over the last year, Tiziana Life Sciences shares have traded in a share price range of US$ 1.08 to US$ 2.60.

Tiziana Life Sciences currently has 129,307,401 shares in issue. The market capitalisation of Tiziana Life Sciences is US$150 million. Tiziana Life Sciences has a price to earnings ratio (PE ratio) of -7.96.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a...

Form 3 - Initial statement of beneficial ownership of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.02	-1.69491525424	1.18	1.28	1.16	132778	1.22546832	DR
4	-0.38	-24.6753246753	1.54	1.85	1.08	274856	1.39363212	DR
12	-0.1	-7.93650793651	1.26	1.85	1.08	200459	1.34658999	DR
26	-0.6	-34.0909090909	1.76	1.85	1.08	227627	1.45737319	DR
52	-0.24	-17.1428571429	1.4	2.6	1.08	282554	1.73362944	DR
156	0.39	50.6493506494	0.77	2.6	0.41	322876	1.20820765	DR
260	-1.27	-52.2633744856	2.43	2.84	0.41	272916	1.27679543	DR